Epigenetic regulations in the IFNγ signalling pathway: IFNγ-mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
// Veronika Vlková 1 , Ivan Štěpánek 1 , Veronika Hrušková 1 , Filip Šenigl 2 , Veronika Mayerová 1 , Martin Šrámek 1 , Jana Šímová 1 , Jana Bieblová 1 , Marie Indrová 1 , Tomáš Hejhal 1 , Nicolas Dérian 3,4,5,6 , David Klatzmann 3,4,5,6 , Adrien Six 3,4,5,6 and Milan Reiniš 1 1 Department of Tumour Immunology, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, v. v. i., Prague 2 Department of Viral and Cellular Genetics, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, v. v. i., Prague 3 Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, Immunology-Immunopathology-Immunotherapy (I3), Paris, France 4 CNRS, FRE 3632, Immunology-Immunopathology-Immunotherapy (I3), Paris, France 5 INSERM, UMR_S 959, Immunology-Immunopathology-Immunotherapy (I3), Paris, France 6 AP-HP, Hôpital Pitié-Salpêtrière, CIC-BTi Biotherapy & Département Hospitalo-Universitaire (DHU) Inflammation-Immunopathology-Biotherapy (i2B), Paris, France Correspondence: Milan Reiniš, email: // Keywords : IFNγ signalling, DNA demethylation, 5-azacytidine, MHC class I downregulation, tumour immunology Received : July 4, 2014 Accepted : July 13, 2014 Published : July 15, 2014 Abstract Downregulation of MHC class I expression on tumour cells, a common mechanism by which tumour cells can escape from specific immune responses, can be associated with coordinated silencing of antigen-presenting machinery genes. The expression of these genes can be restored by IFNγ. In this study we documented association of DNA demethylation of selected antigen-presenting machinery genes located in the MHC genomic locus ( TAP-1, TAP-2, LMP-2, LMP-7 ) upon IFNγ treatment with MHC class I upregulation on tumour cells in several MHC class I-deficient murine tumour cell lines (TC-1/A9, TRAMP-C2, MK16 and MC15). Our data also documented higher methylation levels in these genes in TC-1/A9 cells, as compared to their parental MHC class I-positive TC-1 cells. IFNγ-mediated DNA demethylation was relatively fast in comparison with demethylation induced by DNA methyltransferase inhibitor 5-azacytidine, and associated with increased histone H3 acetylation in the promoter regions of APM genes. Comparative transcriptome analysis in distinct MHC class I-deficient cell lines upon their treatment with either IFNγ or epigenetic agents revealed that a set of genes, significantly enriched for the antigen presentation pathway, was regulated in the same manner. Our data demonstrate that IFNγ acts as an epigenetic modifier when upregulating the expression of antigen-presenting machinery genes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617 · cited 1×
“IFNγ is a cytokine with pleiotropic effects on tumour cells, which is also considered as a crucial mediator of effective antitumour immunity displaying direct impacts on tumour cells [22].”
Background
Cited by
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636568 · Cited by 1,077
The urgent need to recover MHC class I in cancers for effective immunotherapy
Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M., & van Hall, T. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.007 · Cited by 585
“Interestingly, IFN-ginduced restoration of ‘soft’ lesions of MHC-I, one of the most powerful inducers of this gene, was shown to partly mediate its effect by inducing demethylation of antigenprocessing machinery related genes, including the TAP genes and LMP-2 [51].”
BackgroundCancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
Emens, L. A., Ascierto, P. A., Darcy, P. K., Demaria, S., Eggermont, A. M. M., Redmond, W. L., Seliger, B., & Marincola, F. M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.035 · Cited by 566
Improving radiotherapy in cancer treatment: Promises and challenges
Chen, H. H. W., & Kuo, M. T. (2017) · Oncotarget · doi:10.18632/oncotarget.18409 · Cited by 372
Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
Shafer, P., Kelly, L. M., & Hoyos, V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835762 · Cited by 270
HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy
Anderson, P., Aptsiauri, N., Ruiz-Cabello, F., & Garrido, F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00634-7 · Cited by 107
Metadata
- Authors
- Vlková, V., Štěpánek, I., Hrušková, V., Šenigl, F., Mayerová, V., Šrámek, M., Šímová, J., Bieblová, J., Indrová, M., Hejhal, T., Dérian, N., Klatzmann, D., Six, A., & Reiniš, M.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-07-15
- Volume
- 5
- Issue
- 16
- Pages
- 6923-6935
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2135320283
- Cited by
- 39
- References
- 1
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.